OKYO Pharma Announces Randomized Segment Now Underway In Phase 2 Clinical Trial Of Topical Ocular OK-101 For Dry Eye Disease
Portfolio Pulse from Benzinga Newsdesk
OKYO Pharma has announced that the randomized segment of its Phase 2 clinical trial for topical ocular OK-101, a treatment for dry eye disease, is now underway.
June 06, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OKYO Pharma's Phase 2 clinical trial for topical ocular OK-101, a treatment for dry eye disease, has entered the randomized segment, potentially bringing the company closer to a new product offering.
The progression of the Phase 2 clinical trial for OK-101 indicates that the company is moving forward with its research and development efforts. This could potentially lead to a new product offering for dry eye disease, which would expand OKYO Pharma's portfolio and potentially increase its revenue. As a result, the stock price is likely to go up in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100